Comparing Two New Heart Valve Replacement Devices
Part of Heart & circulation clinical trials.
This trial compares two of the newest transcatheter aortic valve devices—the SAPIEN 3 Ultra Resilia and Evolut FX—to see which works better for patients with severe aortic stenosis (a narrowed aortic valve). Both devices are placed through a catheter without open surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have severe aortic stenosis (a significantly narrowed aortic valve confirmed by heart imaging)
- You have symptoms like shortness of breath, chest discomfort, or fatigue during normal activities (NYHA Class II–IV)
- Your heart team agrees that catheter-based valve replacement is the right treatment for you
- Your heart anatomy (assessed by CT scan) is suitable for both valve types being tested
- You can take blood-thinning medications and attend all follow-up appointments for at least 1 year
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows patients with severe aortic stenosis who get a new heart valve (the SAPIEN 3 Ultra RESILIA) through a less invasive procedure (TAVR). Researchers want to see how well this valve works over time using special heart ultrasound tests.
This trial tests two different replacement heart valves (Allegra and Sapien) to see which works better for people who need a new valve placed inside a previously implanted surgical valve. It aims to help patients with a failing biological aortic valve who are already scheduled for this procedure.
This trial studies a new “valve-in-valve” procedure to treat a failing aortic bioprosthetic valve. It may help people improve blood flow through the heart valve and reduce valve-related problems.
This trial tests a new version of a heart valve (SAPIEN X4) placed without open-heart surgery. It's for people with severe aortic stenosis who have symptoms like shortness of breath or chest pain.
This study compares regular monitoring (“clinical surveillance”) versus replacing the aortic valve using a minimally invasive procedure called TAVR for people with moderate aortic stenosis. It aims to see which approach better reduces symptoms or heart damage over time.
This study is testing a new heart valve called the SAPIEN 3 Ultra RESILIA valve for people with severe aortic stenosis. Researchers want to see how well it works and how safe it is over 10 years after a minimally invasive valve replacement procedure called TAVI.
Hear when a new Severe Aortic Valve Stenosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.